NFE2L2 and papillary renal cell carcinoma: A similar pattern of NRF2 mutations was also observed in head and neck carcinoma [154], hepatocellular carcinoma [155], and papillary renal cell carcinoma (PRCC) [156] as well as esophageal and skin cancers, resulting in increased malignant potential and chemoresistance [157].